Background. We investigated the association between polymorphisms of human papillomavirus (HPV)-33 and squamous intraepithelial lesions (SILs).
def ne women at the highest risk of disease progression. Infection with non-European HPV-16 variants or with amino-acid substitutions in E6 (L83V or E31G) has been associated with cervical cancer and persistence of infection [2] [3] [4] [5] .
HPV-33 is closely related phylogenetically to HPV-16 in species A9 of the genus a-papillomavirus [6] . In a recent meta-analysis, HPV-33 was the fourth most frequent high-risk genotype in invasive cancer samples in North America [7] . When the prevalence ratio between invasive cancer and high-grade squamous intraepithelial lesions (HSILs) was examined, HPV-33 ranked fourth, after types 16, 18, and 45 [8] . In sexually active women at risk for or infected with HIV, HPV-33 polymorphisms of the long control region (LCR) were associated with persistence of HPV infection, which is a strong marker for the risk of developing HSILs [9] . However, because of the high proportion of infection with multiple HPV types in that study, it was impossible to investigate the impact of HPV-33 polymorphism on grade of cervical disease. If HPV-33 polymorphisms are indeed a determinant of persistence of infection [9] , they may be associated with HSILs. The aim of the present study was to investigate the distribution of variants of HPV-33 in women without cervical cytological abnormalities or with low-grade SILs (LSILs), HSILs, or cancer. We studied polymorphisms of the regulatory region of HPV (LCR) and of the transforming genes encoding E6 and E7 oncoproteins in Brazilian and Canadian women enrolled in 2 cohort studies and 2 case-control studies, which enabled us to characterize new molecular variants of HPV-33.
MATERIALS AND METHODS
Study sites and design. The present study was conducted on cervical cytobrush samples obtained from 89 (1.7%) women who tested positive for HPV-33 by consensus L1 polymerase chain reaction (PCR) from among 5347 subjects participating in 4 epidemiological studies: 10 women were from a study of the associations between herpes simplex virus (HSV) and cervical lesions (the HPV-HSV study), 43 were from a case-control study designated the "Biomarkers of Cervical Cancer Risk" (BCCR) study, 21 were from the Ludwig-McGill cohort study, and 15 were from the McGill-Concordia cohort study.
The HPV-HSV study was a molecular epidemiologic study conducted in Montreal, Canada, that included 439 women (50 with invasive cancer, 65 with HSILs, 80 with LSILs, and 244 with healthy cervices) to examine the association between HSV and HPV coinfection and cervical cancer [10] . Participants were a median of 33 years old. HPV was detected in 87.2% and 19.7% of women with cervical lesions and healthy cervices, respectively. The BCCR is an ongoing hospital-based case-control study that has recruited 1759 women (1263 with healthy cervices, 60 with LSILs, 408 with HSILs, 18 with cancer, and 10 for whom results were pending) living in Montreal, Canada, to study biomarkers associated with HSILs [11] . Participants were a mean of 32 years old. In the BCCR study, 95.8% of case patients and 31.2% of control subjects were HPV positive [11] . In both of these studies, control subjects were women with current and previously normal annual routine Pap smears, whereas case patients had histologically confi med cervical intraepithelial neoplasia or invasive cancer. The Ludwig-McGill cohort study was conducted in São Paulo, Brazil, and included 2528 women (median age, 33 years), and the McGill-Concordia cohort was conducted in Montreal, Canada, and included 621 young women (median age, 21 years)-the purpose of both studies was to investigate the natural history and persistence of HPV infection [12, 13] . Nearly 53% and 26.2% of participants had at least 1 HPV-positive result in the McGill-Concordia and the Ludwig-McGill cohorts, respectively [12, 13] . These women were monitored prospectively at specifie intervals over the course of the studies, as described elsewhere [12, 13] . Women with repeated normal Pap smears were considered to have healthy cervices, and the highest grade of SIL on cytological results was used for women with repeated abnormal smears.
Informed consent was obtained from all study participants for HPV analysis and other study procedures. Ethics committees from each participating institution approved procedures and consent forms. For each study, standardized questionnaires were administered. Exfoliated cervical cells were collected with a cytobrush and processed using QIAamp columns (Qiagen) [13] , spin-column chromatography [12] , or the Master pure procedure [10, 11] . Samples were considered to be adequate if b-globin DNA could be amplifie with PC04 and GH20 primers. HPV DNA was amplifie using MY09-MY11-HMB01 [12, 13] or PGMY [10] [11] [12] primers and was typed with either the line-blot assay (Roche Molecular Systems) or radiolabeled typespecifi probes [12, 14] . One sample from each HPV-33-positive participant in the above studies was further tested for HPV-33 polymorphisms. Consecutive samples were also tested for women participating in the Ludwig-McGill cohort study who had persistent HPV-33 infection ( women) and n p 14 provided a total of 30 cervical samples (median, 2; mean ‫ע‬ SD, ; range, 2-5). 2.6 ‫ע‬ 0.8 Analysis of HPV-33 LCR, E6, and E7 by PCR sequencing. For each region of the HPV genome, 2 mL of processed specimen was amplifie in a 9600 thermal cycler (Perkin-Elmer). LCR, E6, and E7 were amplifie in a 100-mL reaction volume that contained 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 2.5 U of AmpliTaq Gold enzyme (Roche Diagnostic Systems), 2.0 mmol/L MgCl 2 , 0.5 mmol/L each primer, and 0.25 mmol/ L each dCTP, dTTP, dGTP, and dATP. A 542-bp segment be- 
Nucleotide positions where variations were detected are shown. Positions for which no variation was encountered, compared with the prototype, are indicated by a hyphen, whereas a letter showing the mutated base indicates the variation site. The designation of variants was arbitrary. Frequency indicates the no. of isolates identified for each variant. Changes in amino acid (AA) are also shown.
tween 7337 and 7878 nt at the 5 end of the LCR was generated with primers HPV-33-LCR-1 and HPV-33-LCR-2, a 562-bp fragment between nt 35 and 596 that contained the complete E6 gene was generated with primers HPV-33-E6-1 and HPV-33-E6-2, and a 412-bp fragment between nt 529 and 940 containing the complete E7 gene was generated with primers HPV-33-E7-1 and HPV-33-E7-2, using the amplificatio protocols described by Gagnon et al. [9] . The HPV-33 E6 amplicon contained the complete 483-bp E6 gene. The HPV-33 E7 amplicon contained the complete 324-bp E7 gene. HPV-33 E6 and E7 amplicons overlapped by 68 bp.
After gel electrophoresis on 2% agarose gel, PCR-amplifie HPV-33 DNA amplicons were purifie as described elsewhere [15] . Direct double-stranded PCR sequencing was performed for the LCR, E6, and E7 amplicons with the same primers as those described above, using the fluo escent cycle-sequencing method (BigDye Terminator Ready Reaction kit; Perkin-Elmer), on 20 ng of purifie amplicons. Cycle parameters were 25 cycles of 10 s at 96ЊC, 5 s at 50ЊC, and 4 min at 62ЊC. Sequence analysis was performed on an ABI Prism 3100 genetic-analyzer system (at the Service de Séquencage du Centre de Recherche, Centre Hospitalier de l'Université de Montréal). Nonprototypic isolates were sequenced at least twice, to exclude Taq-induced errors.
The firs HPV-33 isolate, designated as the prototype, was initially sequenced by Cole and Streek [16] . Sequences from variants other than the prototype were aligned for classificatio by use of CLUSTAL W software (version 1.8). A phylogenetic tree was constructed on the basis of the neighbor-joining algorithm, using Mega software (version 2.1). To assess the effect of LCR variations on putative binding sites for cellular proteins, TFSEARCH software (version 1.3) was used.
Data analysis. Because the prevalence of each molecular variant of HPV-33 was often low, the association between HPV-33 variance and HSILs was investigated by classifying isolates into 2 categories: prototype-like and non-prototype-like strains. Non-prototype-like strains had nonsynonymous variations in E6 or E7 or variations in LCR modifying putative cellular transcription-factor binding sites, compared with the prototype. The magnitude of the associations between HPV variants with HSILs was assessed by calculating odds ratios (ORs) and respective 95% confidenc intervals (CIs). Fisher's exact test was used to assess the significanc of the associations between dichotomous variables. Unconditional multiple logistic-regression analysis was performed to obtain maximum-likelihood estimates of ORs while controlling for the confounding effects of age, ethnicity, and study site. Statistical analyses were performed using STATISTICA software (version 6; StatSoft).
RESULTS
In total, 89 (1.7%) of 5344 participants from 4 studies provided at least 1 cervical specimen that contained HPV-33 DNA. Table  1 shows the age and distribution of participants according to study site and grade of cervical disease. The diagnosis of cervical disease was established by histopathologic analysis (14 HSILs and 3 LSILs) or cytologic results (1 HSILs and 4 LSILs). Women were classifie as healthy by histopathologic analysis ( ) n p 4 or by repeated normal cervical-smear results ( ). Seventyn p 60 one (79.8%) women were white, 12 (13.5%) were of African NOTE. Variants are MT (Montreal) or BR (Brazil), followed by the variant no. The no. of isolates tested overall from MT and BR are shown in the "Frequency" columns. origin, 2 (2.2%) were Asian, and 4 (4.5%) were of unknown ethnicity. Sixty-eight were Canadian, and 21 were Brazilian.
Genomic polymorphism of LCR, E6, and E7 in HPV-33. A visible band was obtained from sequencing LCR, E6, and E7 for 85, 89, and 89 isolates, respectively. Tables 2-4 shows the site and nature of variations in LCR, E6, and E7. Table 2 shows the nature and loss or gain in putative cellular transcriptionfactor binding sites of variations in LCR, and tables 3 and 4 show changes in amino-acid sequences in E6 and E7, respectively, compared with the HPV-33 prototype. Some of the variants that we describe in the present article are identical to those described in our initial work and are identifie by the same abbreviations [9] . The proportion of polymorphic nucleotides was significantl greater in the LCR than in the viral oncogenes: 94 variation sites over 502 nt (18.7%) define 14 HPV-33 LCR variants, compared with 13 variation sites (2.7%) over 484 nt definin 8 HPV-33 E6 variants and 7 variation sites (2.2%) over 324 nt definin 8 HPV-33 E7 variants. Deletions were found only in LCR. In addition to the 10 HPV-33 LCR, 5 HPV-33 E6, and 5 HPV-33 E7 variants described elsewhere, we identifie 7, 4, and 4 new variants in LCR (33-LCR-11 to 33-LCR-17), E6 (33-E6-6 to 33-E6-9), and E7 (33-E7-6 to 33-E7-9), respectively [9] . The greatest differences between any 2 variants were 17.5% (88 variations over 502 nt) between 33-LCR-14 and 33-LCR-8, 2.3% (11 variations over 484 nt) between 33-E6-7 and 33-E6-5, and 1.9% (6 variations over 324 nt) between 33-E7-5 and 33-E7-8.
Variability in the 3 regions of the HPV-33 genome was assessed by comparing the number of nucleotide variation sites per isolate after adjusting for the length of amplicon sequenced (502 bp for LCR, 484 bp for E6, and 324 bp for E7) and considering the 78-bp deletion to be 1 variation. As shown in table 5, 25 variants, including the prototype, could be define by combining variations in all 3 regions of the HPV-33 genome. All prototypic LCR variants were also prototypes for E6 and E7. Only 4 variants, including the prototype, were encountered in 15 women. The evolutionary relationship among the 25 HPV-33 variants was explored by subjecting the sequence data to phylogenetic analysis based on the neighbor-joining method (figu e 1). HPV-33 variants clustered into 2 major lineages, 1 of which included the prototype.
HPV-33 polymorphisms and ethnicity. As shown in table 5, the HPV-33 prototype was more common among partici- ). HPV-33 variants were not P p .001 associated with ethnicity, irrespective of the country of recruitment (data not shown).
HPV-33 polymorphisms, persistence of HPV infection, and grade of cervical lesions. A range of 2-5 consecutive samples positive for HPV-33 from 11 women in the Ludwig-McGill cohort study was tested for HPV-33 polymorphisms. Samples from the same woman always contained the same HPV-33 variant. The association between HPV-33 variations and grades of cervical lesions is shown in table 6. In the following analyses, not all participants could be included, because some specimens could not be sequenced (see above). Non-prototype-like LCR variants were significantl associated with HSILs, in contrast to E6 or E7 (table 6) .
Of the 9 variations in the LCR resulting in the loss or gain in putative binding sites for cellular factors, only C7732G was significantl associated with HSILs (table 6). Adjusting for ethnicity generated similar results (data not shown). When only Canadian women were considered in the analysis, the association remained significan after we corrected for age and ethnicity (OR, 4.0 [95% CI, 1.
2-17.2];
). The variation at P p .03 nt 7732 resulted in the loss of a putative binding site for upstream stimulatory factor (USF). Putative binding sites near the USF binding site were also identifie for transactivating factors such as the octamer binding factor and activator protein 1. The loss of the 78-bp duplication in LCR was detected more frequently in women with HSILs (42.9%) than in healthy women (24.2%), but this difference did not reach statistical significanc (table 6). At least 1 HPV type was detected in 41 (6.1%) healthy women and 8 (53.3%) women with HSILs, and high-risk HPV type other than 33 was detected in 38 (59.4%) healthy women and 7 (46.7%) women with HSILs. The presence of an HPV type other than 33 (OR, 0.6 [95% CI, 0.2-1.7]) or of a highrisk HPV type other than 33 (OR, 0.5 [95% CI, 0.2-1.6]) was not associated with the presence of HSILs.
DISCUSSION
In the present study, we analyzed sequence variations in the LCR, E6, and E7 genes from HPV-33 isolates collected from women without cervical lesions or those with LSILs or HSILs 
NOTE.
Odds ratio (OR) estimates and 95% confidence intervals (CIs) were obtained using crude logistic regression. Adjusted ORs were adjusted for age and study site. LCR, long control region.
in Canada and Brazil. Our data indicate that LCR but not E6 or E7 polymorphisms are associated with high-grade disease. As opposed to HPV-16, HPV-33 polymorphisms were not associated with ethnicity, although the detection rates of some HPV-33 variants were different between the 2 countries. Limited data on HPV-33 polymorphisms have been published to date. Because it includes data from 89 women with different stages of cervical disease, recruited in different studies and countries, the present work represents one of the most comprehensive studies on HPV-33 polymorphisms.
L1 and E6 variations were firs reported in HPV-33 isolates from samples of invasive cervical cancer [17, 18] . We recently reported on HPV-33 polymorphisms in HIV-seropositive women [9] . Using the results from these publications, we found several new variation sites in LCR (nt 7424, 7436, 7536, 7545, and 7768), E6 (nt 191, 213, 364, and 480), and E7 (nt 608 and 737). As for other HPV types, variations were not randomly distributed and variation sites were shared by several isolates and variants [9, 15, [19] [20] [21] [22] [23] .
As has been reported for other HPV types, E6 and E7 were less variable than LCR [5, 9, 15, 24, 25] . The nonsynonymous L83V variation at nt 355 of HPV-33 has been described in HPV-16 at nt 350. This HPV-16 variation was associated in some studies with HSILs, although that result remains controversial [26] [27] [28] [29] [30] . In our studies of HPV-33, the L83V variation was not associated with HPV persistence or the risk of HSILs [9] . The phylogenetic tree generated by combining sequences from LCR, E6, and E7 was dichotomic, as has been reported for HPV types other than 16 or 18, whereas trees constructed with HPV-16 variants have several branches [5, 9, 15, 23, 25, 31, 32] . HPV-16, -18, and -52 polymorphisms have been strongly associated with ethnicity [5, 15, 31] . A relationship with ethnicity was not as clear for HPV-33 polymorphisms. Only 1 HPV-33 variant was detected more frequently in 1 country. Isolates from several countries should be analyzed to further study the association between ethnicity and HPV-33 variations. Most HPV-33 variants in the present study were rare and were detected only once or twice.
A variation at nt 7732 in LCR resulting in the loss of a putative binding site for USF was associated with HSILs. The association remained significan even after adjustment for ethnicity (an important potential confounder) and study site [4] . USF, a transcription factor in humans that is also important for the expression of the adenovirus major late promoter, serves as a negative regulator of cellular proliferation [33] . The effect of USF on the HPV promoter has never been investigated. Losing a binding site for a potential transactivator should not theoretically cause a predisposition to greater pathogenic potential. Several putative binding sites for various cellular factors were also located near the putative USF binding site. Loss of a binding site for USF could allow for less competition between these factors, which may be stronger transactivators of the HPV promoter. This variation could also be associated with HSILs, because it cosegregated with another variation elsewhere in the viral genome that could result in changes in the functional or antigenic domains of HPV-33 [5] . If this is the case, the nonsynonymous variation will be in genes other than E6 or E7. A previous study of a limited number of women reported that the HPV-33 E6 prototype was more frequently detected in cervical intraepithelial neoplasia (CIN)-3 than in CIN-1 or CIN-2 [18] . Our results in a greater number of women do not confi m this conclusion.
Several studies have demonstrated that some LCR variations are associated with a greater risk of HPV persistence or HPVinduced lesions [5, [34] [35] [36] . The transcription of HPV onco- genes is under the control of promoter and enhancer elements in LCR that also contain several putative binding sites for cellular transcription factors that can modulate its function positively or negatively [37] . HPV-16 variants in Asian American women have been shown to have a greater transcriptional activity than variants in European women, because of increased activity of the p97 promoter in LCR [35, [38] [39] [40] . The same has been reported for HPV-18 with p105 promoter activities [41] . LCR variations resulting in the loss of YY1 binding sites have shown enhanced transcriptional activity [42] . Most of the increased activity of the LCR maps to its 3 half-the region that we analyzed for HPV-33 [35] . We also reported that a variation in the LCR of HPV-52 increased the risk of persistence in HIVseropositive women [43] .
The loss of the 78-bp duplication in LCR has been associated with the persistence of HPV infection, which a surrogate marker for HSILs [9] . The perfect 78-bp tandem repeats after the putative origin of replication in LCR are a feature unique to HPV-33 [16] . Our work confi med the presence of the duplication in several isolates. The 78-bp deletion resulted in the loss of a putative binding site for c-myb. The 78-bp repeats could act as repressors of LCR, and their loss could predispose to persistence and HSILs. Tandem repeats found in SV40 [44] repress viral replication by competition between c-myb and transactivators for binding LCR. To truly reach statistical significance we would need to test more women with HSILs. This could not be achieved by combining our studies. To determine whether the duplication plays a role in persistence and the progression of SILs, we would also need to compare women with persistent infection, LSILs, and HSILs in large-scale prospective studies.
Seven women from our 2 cohort studies did not have SILs according to repeated normal cervical-smear results. However, they had persistent HPV-33 infection. These women were at greater risk of developing SILs. The exclusion of these women from the control group did not modify the results of the analysis (data not shown). The lack of a control in case-control studies for the persistence of HPV infection and its potential role in the misclassificatio of participants is a weakness. It may be difficul in case-control designs to investigate biomarkers of HSILs independently from persistence, and this could impede our ability to fin an association between loss of duplication and HSILs. Misclassificatio could explain, in part, the discrepancies in the literature about the role of viral polymorphisms in HSILs [5] .
The number of HPV-33-infected women in our cohorts was too small to investigate the impact of the loss of duplication on viral persistence. As we have previously shown for HPV-16 and other types, all women with consecutively HPV-33-positive specimens were infected by the same variant [9, 12, 43, 45] . Another caveat of our work is the fact that our outcome definition was based on cytologic results for healthy women. The classificatio of a woman as being healthy was based on several consecutive normal Pap smears, which greatly reduced the likelihood of the presence of an underlying lesion. Most lesions were confi med by histologic analysis. The number of participants was limited, and the different study designs may have introduced bias. However, we controlled for the study in which recruitment was done in multivariate analysis.
The present results confi m the need to evaluate the role of polymorphisms in HPV types other than 16 to better understand the natural history and predisposing factors to HSILs. The present results also highlight a limitation of case-control studies in the investigation of the role of viral polymorphisms in HSILs or cancer. Polymorphisms associated with viral persistence and HSILs may not be properly investigated using this study design because of the misclassificatio of control subjects. Large-scale prospective studies could help solve the potential misclassificatio of control subjects, especially for frequently occurring types, such as HPV-16. However, the power of these studies will be weaker for rarer types. Common patterns of polymorphism across types will probably not be found.
